Duration of Isolation and Precautions for Adults with COVID-19

Accumulating proof helps ending isolation and precautions for individuals with COVID-19 utilizing a symptom-based technique. This replace incorporates latest proof to tell the length of isolation and precautions beneficial to stop transmission of SARS-CoV-2 to others, whereas limiting pointless extended isolation and pointless use of laboratory testing assets.

Key findings are summarized right here.

  1. Concentrations of SARS-CoV-2 RNA measured in higher respiratory specimens decline after onset of signs (CDC, unpublished information, 2020; Midgley et al., 2020; Young et al., 2020; Zou et al., 2020; Wölfel et al., 2020; van Kampen et al., 2020).
  2. The probability of recovering replication-competent virus additionally declines after onset of signs. For sufferers with gentle to reasonable COVID-19, replication-competent virus has not been recovered after 10 days following symptom onset (CDC, unpublished information, 2020; Wölfel et al., 2020; Arons et al., 2020; Bullard et al., 2020; Lu et al., 2020; private communication with Young et al., 2020; Korea CDC, 2020). Recovery of replication-competent virus between 10 and 20 days after symptom onset has been documented in some individuals with extreme COVID-19 that, in some circumstances, was difficult by immunocompromised state (van Kampen et al., 2020). However, on this sequence of sufferers, it was estimated that 88% and 95% of their specimens now not yielded replication-competent virus after 10 and 15 days, respectively, following symptom onset.
  3. A big contact tracing examine demonstrated that high-risk family and hospital contacts didn’t develop an infection if their publicity to a case affected person began 6 days or extra after the case affected person’s sickness onset (Cheng et al., 2020).
  4. Although replication-competent virus was not remoted Three weeks after symptom onset, recovered sufferers can proceed to have SARS-CoV-2 RNA detected of their higher respiratory specimens for as much as 12 weeks (Korea CDC, 2020; Li et al., 2020; Xiao et al, 2020). Investigation of 285 “persistently positive” individuals, which included 126 individuals who had developed recurrent signs, discovered no secondary infections amongst 790 contacts attributable to contact with these case sufferers. Efforts to isolate replication-competent virus from 108 of those case sufferers had been unsuccessful (Korea CDC, 2020).
  5. Specimens from sufferers who recovered from an preliminary COVID-19 sickness and subsequently developed new signs and retested optimistic by RT-PCR didn’t have replication-competent virus detected (Korea CDC, 2020; Lu et al., 2020). The threat of reinfection could also be decrease within the first Three months after preliminary an infection, primarily based on restricted proof from one other betacoronavirus (HCoV-OC43), the genus to which SARS-CoV-2 belongs (Kiyuka et al, 2018).
  6. Currently, 6 months after the emergence of SARS-CoV-2, there have been no confirmed circumstances of SARS-CoV-2 reinfection. However, the variety of areas the place sustained an infection stress has been maintained, and due to this fact reinfections could be almost definitely noticed, stays restricted.
  7. Serologic or different correlates of immunity haven’t but been established.

The present proof contains the next caveats:

  • In a latest examine of expert nursing facility employees adopted prospectively for asymptomatic an infection, certainly one of 48 contaminated employees had a nasopharyngeal swab which was weakly optimistic on a single-passage plaque assay greater than 20 days after preliminary prognosis; nevertheless, the specimen was not subjected to serial passage to reveal the presence of replication-competent virus (Quicke et al., 2020).
  • In one case report, an individual with gentle sickness offered specimens that yielded replication-competent virus for as much as 18 days after symptom onset (Liu et al., 2020).
  • Data at present obtainable are derived from adults; equal information from kids and infants usually are not presently obtainable.
  • More information are wanted regarding viral shedding in some conditions, together with in immunocompromised individuals.


Available information point out that individuals with gentle to reasonable COVID-19 stay infectious now not than 10 days after symptom onset. Persons with extra extreme to important sickness or extreme immunocompromise possible stay infectious now not than 20 days after symptom onset.  Recovered individuals can proceed to shed detectable SARS-CoV-2 RNA in higher respiratory specimens for as much as Three months after sickness onset, albeit at concentrations significantly decrease than throughout sickness, in ranges the place replication-competent virus has not been reliably recovered and infectiousness is unlikely. The etiology of this persistently detectable SARS-CoV-2 RNA has but to be decided. Studies haven’t discovered proof that clinically recovered individuals with persistence of viral RNA have transmitted SARS-CoV-2 to others. These findings strengthen the justification for counting on a symptom primarily based, moderately than test-based technique for ending isolation of those sufferers, in order that individuals who’re by present proof now not infectious usually are not saved unnecessarily remoted and excluded from work or different obligations.

Reinfection with SARS-CoV-2 has not but been definitively confirmed in any recovered individuals thus far. If, and in that case when, individuals will be reinfected with SARS-CoV-2 stays unknown and is a topic of investigation. Persons contaminated with associated endemic human betacoronavirus seem to grow to be prone once more at round 90 days after onset of  an infection. Thus, for individuals recovered from SARS-CoV-2 an infection, a optimistic PCR in the course of the 90 days after sickness onset extra possible represents persistent shedding of viral RNA than reinfection.

  • If such an individual stays asymptomatic throughout this 90-day interval, then any re-testing is unlikely to yield helpful data, even when the particular person had shut contact with an contaminated particular person.
  • If such an individual turns into symptomatic throughout this 90-day interval and an analysis fails to determine a prognosis apart from SARS-CoV-2 an infection (e.g., influenza), then the particular person might warrant analysis for SARS-CoV-2 reinfection in session with an infectious illness or an infection management skilled. Quarantine could also be warranted throughout this analysis, notably if signs developed after shut contact with an contaminated particular person.

Correlates of immunity to SARS-CoV-2 an infection haven’t been established. Specifically, the utility of serologic testing to ascertain the absence or presence of an infection or reinfection stays undefined.

The suggestions under are primarily based on the perfect data obtainable in mid-July 2020 and mirror the realities of an evolving pandemic. Even for pathogens for which a few years of knowledge can be found, it is probably not attainable to ascertain suggestions that guarantee 100% of individuals who’re shedding replication-competent virus stay remoted. CDC will proceed to carefully monitor the evolving science for data that may warrant reconsideration of those suggestions.


  1. Duration of isolation and precautions
    • For most individuals with COVID-19 sickness, isolation and precautions can typically be discontinued 10 days after symptom onset1 and determination of fever for at the very least 24 hours, with out the usage of fever-reducing drugs, and with enchancment of different signs.
      • A restricted variety of individuals with extreme sickness might produce replication-competent virus past 10 days which will warrant extending length of isolation and precautions for as much as 20 days after symptom onset; contemplate session with an infection management consultants.
    • For individuals who by no means develop signs, isolation and different precautions will be discontinued 10 days after the date of their first optimistic RT-PCR check for SARS-CoV-2 RNA.
  2. Role of PCR testing2 to discontinue isolation or precautions
    • For individuals who’re severely immunocompromised, a test-based technique might be thought-about in session with infectious illnesses consultants.
    • For all others, a test-based technique is now not beneficial besides to discontinue isolation or precautions sooner than would happen beneath the technique outlined in Part 1, above.
  3. Role of PCR testing2 after discontinuation of isolation or precautions
    • For individuals beforehand identified with symptomatic COVID-19 who stay asymptomatic after restoration, retesting isn’t beneficial inside Three months after the date of symptom onset for the preliminary COVID-19 an infection. In addition,  quarantine isn’t beneficial within the occasion of shut contact with an contaminated particular person.
    • For individuals who develop new signs in step with COVID-19 in the course of the Three months after the date of preliminary symptom onset, if an alternate etiology can’t be recognized by a supplier, then the particular person might warrant retesting; session with infectious illness or an infection management consultants is beneficial. Quarantine could also be thought-about throughout this analysis primarily based on session with an an infection management skilled, particularly within the occasion signs develop inside 14 days after shut contact with an contaminated particular person.
    • For individuals who by no means developed signs, the date of first optimistic RT-PCR check for SARS-CoV-2 RNA ought to be used instead of the date of symptom onset.
  4. Role of serologic testing
    • Serologic testing shouldn’t be used to ascertain the presence or absence of SARS-CoV-2 an infection or reinfection.

[1] Symptom onset is outlined because the date on which signs first started, together with non-respiratory signs.
[2] PCR testing is outlined as the usage of an RT-PCR assay to detect the presence of SARS-CoV-2 RNA..


  • Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a talented nursing facility. N Engl J Med 2020 May 28;382(22):2081-2090. doi:10.1056/NEJMoa2008457.
  • Bullard J, Durst Okay, Funk D, Strong JE, Alexander D, Garnett L et al. Predicting Infectious SARS-CoV-2 From Diagnostic Samples. Clin Infect Dis 2020 May 22.  doi: 10.1093/cid/ciaa638.
  • Cheng HW, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA Intern Med 2020 May 1; doi:10.1001/jamainternmed.2020.2020.
  • Kiyuka PK, Agoti CN, Munywoki PK, Njeru R, Bett A, Otieno JR, et al. Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya. J Infect Dis 2018 May 5;217(11):1728-1739. doi: 10.1093/infdis/jiy098.
  • Korea Centers for Disease Control and Prevention. Findings from Investigation and Analysis of re-positive circumstances. May 19, 2020. Available at: https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030&act=view&list_no=367267&nPage=1external icon
  • Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA Shedding: Not a Rare Phenomenon. J Med Virol 2020 Apr 29. doi: 10.1002/jmv.25952.
  • Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, et al. Prolonged Virus Shedding Even After Seroconversion in a Patient With COVID-19. J Infect 2020 Apr 10;S0163-4453(20)30190-0.  doi: 10.1016/j.jinf.2020.03.063
  • Lu J, Peng J, Xiong Q, Liu Z, Lin H, Tan X, et al. Clinical, immunological and virological characterization of COVID-19 sufferers that check re-positive for SARS-CoV-2 by RT-PCR. (Preprint) Medrxiv. 2020. Available at: https://www.medrxiv.org/content/10.1101/2020.06.15.20131748v1external icon  doi: https://doi.org/10.1101/2020.06.15.20131748
  • Midgley CM, Kujawski SA, Wong KK, Collins, JP, Epstein L, Killerby ME et al. (2020). Clinical and Virologic Characteristics of the First 12 Patients with Coronavirus Disease 2019 (COVID-19) within the United States. Nat Med 2020 Jun;26(6):861-868. doi: 10.1038/s41591-020-0877-5.
  • Quicke Okay, Gallichote E, Sexton N, Young M, Janich A, Gahm G, et al. Longitudinal Surveillance for SARS-CoV-2 RNA Among Asymptomatic Staff in Five Colorado Skilled Nursing Facilities: Epidemiologic, Virologic and Sequence Analysis. (Preprint) Medrxiv. 2020. Available at: https://www.medrxiv.org/content/10.1101/2020.06.08.20125989v1external icon doi: https://doi.org/10.1101/2020.06.08.20125989external icon
  • van Kampen J, van de Vijver D, Fraaij P, Haagmans B, Lamers M, Okba N, et al. Shedding of infectious virus in hospitalized sufferers with coronavirus disease-2019 (COVID-19): length and key determinants. (Preprint) Medrxiv. 2020. Available at: https://www.medrxiv.org/content/10.1101/2020.06.08.20125310v1external icon doi: https://doi.org/10.1101/2020.06.08.20125310
  • Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. (2020). Virological evaluation of hospitalized sufferers with COVID-2019. Nature 2020 May;581(7809):465-469. doi:10.1038/s41586-020-2196-x
  • Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis 2020;26(8):10.3201/eid2608.200681. doi:10.3201/eid2608.200681
  • Young BE, Ong SWX, Kalimuddin S, Low JG, Ta, SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020 Mar 3;323(15):1488-1494.  doi:10.1001/jama.2020.3204
  • Personal communication with Young BE first writer of preprint of: Young BE, Ong SW, Ng LF, Anderson DE, Chia WN, Chia PY, et al. Immunological and Viral Correlates of COVID-19 Disease Severity: A Prospective Cohort Study of the First 100 Patients in Singapore. (Preprint) SSRN. 2020. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3576846external icon http://dx.doi.org/10.2139/ssrn.3576846
  • Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. (2020). SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med, 382(12), 1177-1179. doi:10.1056/NEJMc200173

Leave a Comment

Item added to cart.
0 items - $0.00